Compare NEOG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | ADPT |
|---|---|---|
| Founded | 1981 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.3B |
| IPO Year | 1995 | 2019 |
| Metric | NEOG | ADPT |
|---|---|---|
| Price | $9.31 | $12.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.67 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 04-09-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $894,661,000.00 | $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | $1.67 | $22.72 |
| P/E Ratio | $111.78 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $4.32 | $6.77 |
| 52 Week High | $11.43 | $20.76 |
| Indicator | NEOG | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 40.74 |
| Support Level | $8.93 | $12.19 |
| Resistance Level | $10.30 | $12.92 |
| Average True Range (ATR) | 0.53 | 0.91 |
| MACD | 0.13 | 0.06 |
| Stochastic Oscillator | 38.58 | 19.62 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.